Table 2.
Baseline characteristics of breast cancer patients with liver metastases in the FUSCC dataset
| Variable | Patients, No. % |
|---|---|
| Patients (n = 1728) | |
| Age at diagnosis, y | |
| 21–40 | 288 (16.7%) |
| 41–60 | 1143 (66.1%) |
| > 60 | 297 (17.2%) |
| Histology | |
| Infiltrating duct carcinoma | 1396 (80.8%) |
| Lobular carcinoma | 31 (1.8%) |
| Other | 301 (17.4%) |
| De novo metastatic diseases | |
| No | 1526 (88.3%) |
| Yes | 202 (11.7%) |
| Surgery of primary site | |
| No | 219 (12.7%) |
| Yes | 1509 (87.3%) |
| Prior Chemotherapy | |
| No | 226 (13.1%) |
| Yes | 1502 (86.9%) |
| Prior Radiotherapy | |
| No | 848 (49.1%) |
| Yes | 785 (45.4%) |
| Unknown | 95 (5.5%) |
| Recurrent sequence | |
| First liver metastases | 1087 (62.9%) |
| Subsequent liver metastases | 641 (37.1%) |
| Extrahepatic metastatic sites to lung, brain, bone and lymph nodes, No | |
| 0 | 561 (32.5%) |
| 1 | 534 (30.9%) |
| 2 | 382 (22.1%) |
| 3 | 223 (12.9%) |
| All 4 | 28 (1.6%) |
| Subtype | |
| HR+/HER2− | 767 (44.3%) |
| HR+/HER2+ | 305 (17.7%) |
| HR−/HER2+ | 321 (18.6%) |
| Triple-negative | 270 (15.6%) |
| Unknown | 65 (3.8%) |
Notes: + denotes positive; − denotes negative; *denotes a statistically significant P-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor